Lanreotide reduces serum free and total insulin-like growth factor-I after angioplasty

Circulation

Volumn 94, Issue 10, 1996, Pages 2465-2471

  Frystyk, Jan ^a   Skjærbæk, Christian ^a   Alexander, Niels ^b   Emanuelsson, Håkan ^c   Suryapranata, Harry ^d   Beyer, Horst ^e   Foegh, Marie ^f   Ørskov, Hans ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b IPSEN   (France)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d HOSPITAL DE WEEZENLANDEN   (Netherlands)

^e Waldkrankenhaus ^*  (Germany)

^f GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

angiography; growth substances; muscle, smooth; proteins

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOPEPTIN; INSULIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RESTENOSIS; RISK FACTOR; SMOOTH MUSCLE FIBER; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR SMOOTH MUSCLE;

EID: 0029807412     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.10.2465     Document Type: Article

References (38)

1. Cercek B, Sharifi B, Barath P, Bailey L, Forrester JS. Growth factors in pathogenesis of coronary arterial restenosis. Am J Cardiol. 1991;68:24C-33C.
2. Austin GE, Ratliff NB, Hollman J, Tabei S, Phillips DF. Intimal proliferation of smooth muscle cell as an explanation for recurrent coronary artery stenosis after percutaneous transluminal angioplasty. J Am Coll Cardiol. 1985;6:369-375.
3. Emanuelsson H, Beatt KJ, Bagger JP, Balcon R, Heikkilä J, Picssens J, Schaeffer M, Suryapranata H, Foegh M. Long-term effects of angiopeptin treatment in coronary angioplasty: reduction in clinical events but not angiographic restenosis. Circulation. 1995;91:1689-1696.
4. Lovqvist A, Emanuelsson H, Nilsson J, Lundqvist H, Carlsson J. Pathophysiological mechanisms for restenosis following coronary angioplasty: possible preventive alternatives. J Intern Med. 1993;233:215-226.
5. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995;16:3-34.
6. Clemmons DR, Van Wyk JJ, Evidence for a functional role of endogenously produced somatomedinlike peptides in the regulation of DNA synthesis in cultured human fibroblasts and porcine smooth muscle cells. J Clin Invest. 1985;75:1914-1918.
7. Delafontaine P, Meng XP, Ku L, Du J. Regulation of vascular smooth muscle cell insulin-like growth factor-I receptors by phosphorothioate oligonucleotides effects on cell growth and evidence that sense targeting at the ATG site increases receptor expression. J Biol Chem. 1995;270:14383-14388.
8. Daughaday WH, Ward AP, Goldberg AC, Trivedi B, Kapadia M. Characterization of somatomedin binding in human serum by ultracentrifugation and gel filtration. J Clin Endocrinol Metab. 1982;55:916-921.
9. Conte J, Foegh M, Calcagno D, Wallace R, Ramwell P. Peptide inhibition of proliferation following angioplasty in rabbits. Transplant Proc. 1989;21:3686-3688.
10. Lundergan C, Foegh ML, Vargas R, Eufemio M, Bormes GW, Kot P, Ramwell P. Inhibition of myointimal proliferation of the rat carotid artery by peptides angiopeptin and BIM 23034. Atherosclerosis. 1989;80:49-55.
11. Foegh ML, Asotra S, Conte JV, Howell M, Kagan E, Verma K, Ramwell PW. Early inhibition of myointimal proliferation by Angiopeptin following balloon catheter injury in the rabbit. J Vasc Surg. 1994;19:1084-1091.
12. Howell M, Ørskov H, Frystyk J, Flyvbjerg A, Grønbæk H, Foegh M. Lanreotide, a somatostatin analogue, reduces insulin-like growth factor I accumulation in proliferating aortic tissue in rabbits in vivo: a preliminary study. Ear J Endocrinol. 1994;130:422-425.
13. Frystyk J, Dinesen B, Ørskov H. Non-competitive time-resolved immunofluorometric assay for determination of human insulin-like growth factor I and II. Growth Regul. 1995;5:169-176.
14. Daughaday WH, Mariz IK, Blethen SL. Inhibition of access of bound somatomedin to membrane receptor and immunobinding sites: a comparison of radioreceptor and radioimmunoassay of somatomedin in native and acid-ethanol-extracted serum. J Clin Endocrinol Metab. 1980;51:781-788.
15. Frystyk J, Skjærbæk C, Dinesen B, Ørskov H. Free insulin-like growth factors (IGF-I and IGF-II) in human serum. FEES Lett. 1994;348:185-191.
16. Kaal A, Frystyk J, Skjærbæk C, Nielsen S, Jorgensen JOL, Bruns C, Marbach P, Lancranjan I, Weeke J, Ørskov H. Effects of intramuscular microsphere-encapsulated octreotide on serum growth hormone, insulin-like growth factors (IGFs), free IGFs, and IGF-binding proteins in acromegalic patients. Metabolism. 1995;44(suppl I): I-6-I-14.
17. Hansson HA, Brandsten C, Lossing C, Petruson K. Transient expression of insulin-like growth factor I immunoreactivity by vascular cells during angiogenesis. Exp Mol Pathol. 1989;50:125-138.
18. Hansson HA, Jennische E, Skottner A. Regenerating endothelial cells express insulin-like growth factor-I immunoreactivity after arterial injury. Cell Tissue Res. 1987;250:499-505.
19. Bornfeldt KE, Arnqvist HJ, Capron L. In vivo proliferation of rat vascular smooth muscle in relation to diabetes mellitus insulin-like growth factor I and insulin. Diabetologia. 1992;35:104-108.
20. Cercek B, Fishbein MC, Forrester JS, Helfant RH, Fagin JA. Induction of insulin-like growth factor I messenger RNA in rat aorta after balloon denudation. Circ Res. 1990;66:1755-1760.
21. Khorsandi MJ, Fagin JA, Giannella Neto D, Forrester JS, Cercek B. Regulation of insulin-like growth factor-I and its receptor in rat aorta after balloon denudation: evidence for local bioactivity. J Clin Invest. 1992;90:1926-1931.
22. Grant MB, Wargovich TJ, Ellis EA, Caballero S, Mansour M, Pepine CJ. Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells: a potential treatment for restenosis? Circulation. 1994;89:1511-1517.
23. Khorsandi M, Fagin JA, Fishbein MC, Forrester JS, Cercek B. Effects of hypophysectomy on vascular insulin-like growth factor-I gene expression after balloon denudation in rats. Atherosclerosis. 1992;93:115-122.
24. Sharp PS, Fallon TJ, Brazier J, Sandier LM, Joplin GF, Kohner EM. Long term follow up of patients who underwent yttrium-90 pituitary implantation for treatment of proliferative diabetic retinopathy. Diabetologia. 1987;30:199-207.
25. Merimee TJ. A follow-up study of vascular disease in growth-hormone-deficient dwarfs with diabetes. N Engl J Med. 1978;298:1217-1222.
26. Fryburg DA, Barrett EJ. Insulin, growth hormone, and IGF-I regulation of protein metabolism. Diabetes Metab Rev. 1995;3:93-112.
27. Flyvbjerg A, Frystyk J, Thorlacius Ussing O, Ørskov H. Somatostatin analogue administration prevents increase in kidney somatomedin C and initial renal growth in diabetic and uninephrectomized rats. Diabetologia. 1989;32:261-265.
28. Kent KM, Williams DO, Cassagneau B, Broderick T, Chapekis A, Simptendorfer C, Cote C, Bates E, Tauscher G, Kuntz RE, Popma C, Foegh M. Double-blind, controlled trial of the effect of angiopeptin on coronary restenosis following balloon angioplasty. Circulation. 1993;88(suppl I):I-506. Abstract.
29. Eriksen VH, Amtorp O, Bagger JP, Emanuelsson H, Foegh M, Henningsen P, Saunamaki K, Schaefffer M, Thayssen P, Ørskov H, Kuntz R, Popma JJ. Randomized double-blind Scandinavian trial of angiopeptin versus placebo for the prevention of clinical events and restenosis after coronary balloon angioplasty. Am Heart J. 1995;130:1-8.
30. Nørgaard K, Snorgaard O, Jensen T, Kirkegaard C. Effects of octreotide on lipoproteins and endothelial function in type 1 (insulin-dependent) diabetic patients. Diabet Med. 1990;7:909-913.
31. Lee PD, Conover CA, Powell DR. Regulation and function of insulin-like growth factor-binding protein-1. Proc Soc Exp Biol Med. 1993;204:4-29.
32. Bach LA, Rechler MM, Insulin-like growth factor binding proteins. Diabetes Metab Rev. 1995;3:38-61.
33. Jones JI, D'Ercole AJ, Camacho Hubner C, Clemmons DR. Phosphorylation of insulin-like growth factor (IGF)-binding protein 1 in cell culture and in vivo: effects on affinity for IGF-I. Proc Natl Acad Sci U S A. 1991;88:7481-7485.
34. Jyung RW, Mustoe JA, Busby WH, Clemmons DR. Increased wound-breaking strength induced by insulin-like growth factor I in combination with insulin-like growth factor binding protein-1. Surgery. 1994;115:233-239.
35. Cox GN, McDermott MJ, Merkel E, Stroh CA, Ko SC, Squires CH, Gleason TM, Russell D. Recombinant human insulin-like growth factor (IGF)-binding protein-1 inhibits somatic growth stimulated by IGF-I and growth hormone in hypophysectomized rats. Endocrinology. 1994;135:1913-1920.
36. Baxter RC. Insulin-like growth factor (IGF) binding proteins: the role of serum IGFBPs in regulating IGF availability. Acta Paediatr Suppl. 1991;372:107-114.
37. Ezzat S, Ren SG, Braunstein GD, Melmed S. Octreotide stimulates insulin-like growth factor binding protein-1 (IGFBP-1) levels in acromegaly. J Clin Endocrinol Metab. 1991;73:441-443.
38. Wolthers T, Grøfte T, Flyvbjerg A, Frystyk J, Vilstrup H, Ørskov H, Foegh M. Dose-dependent stimulation of insulin-like growth factor-binding protein-1 by lanreotide, a somatostatin analog. J Clin Endocrinol Metab. 1994;78:141-144.